📰 Breaking News: Lessons Learnt & Insights from UK’s first and to date only SME Restructuring Plan

Appointment of liquidators (MVL)

A H - Biotech Limited enters members' voluntary liquidation

active Company no. 10900007 Published 26 October 2026

In short: A H - Biotech Limited (company no. 10900007) entered members' voluntary liquidation, a solvent and planned closure, according to a Appointment of liquidators (MVL) notice published in The London Gazette on 26 October 2026. The office holders are Asher Miller; Stephen Katz, appointed 21 October 2026. The company's business: research and experimental development on biotechnology.

The notice announces that members have appointed Asher Miller and Stephen Katz as liquidators of A H - BIOTECH LIMITED in a members’ voluntary liquidation.

Notice details

Company
A H - BIOTECH LIMITED
Company number
10900007
Nature of business
Research and experimental development on biotechnology
Registered office
Pearl Assurance House, 319 Ballards Lane, London, N12 8LY
Type of liquidation
Members
Date of appointment
21 October 2026
Liquidator(s)
Asher Miller; Stephen Katz
Liquidator numbers
IP No. 9251; IP No. 8681
Appointed by
Members

What this notice means

A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.

Read more: What is Liquidation?.

What happens next

Because this is a solvent liquidation, creditors are paid in full. The liquidator advertises for claims, settles them, distributes the surplus to the shareholders and the company is then dissolved. Anyone owed money should still submit their claim to the liquidator named in the notice, and within the period the notice states.

All notices for A H - Biotech Limited

3 Gazette notices on record for company no. 10900007, newest first. The full history, with last filed accounts, is on the A H - Biotech Limited company record.

  1. Notices to creditors (MVL) 26 Oct 2026
  2. Resolution for winding up (MVL) 26 Oct 2026

How does this notice affect you?

Choose what applies and we'll point you at the right next step.

Related guidance

Free, practical guides from K2 on what this kind of notice means for directors.

More liquidation notices

← Back to all notices

Frequently asked questions

Is A H - Biotech Limited in financial difficulty?

No — this is a solvent process. A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress. The London Gazette published a Appointment of liquidators (MVL) for A H - Biotech Limited (company no. 10900007) on 26 October 2026.

What does a Appointment of liquidators (MVL) mean?

A members' voluntary liquidation (MVL) is the solvent, orderly winding-up of a company that can pay its debts in full — usually part of a director's retirement, a group restructure, or closing a company that has served its purpose. It is a planned closure, not a sign of financial distress.

What happens next?

Because this is a solvent liquidation, creditors are paid in full. The liquidator advertises for claims, settles them, distributes the surplus to the shareholders and the company is then dissolved. Anyone owed money should still submit their claim to the liquidator named in the notice, and within the period the notice states.

Who is dealing with the liquidation?

The office holders named in the notice: Asher Miller; Stephen Katz, appointed 21 October 2026. Creditors, employees and anyone holding goods or money belonging to the company should contact them directly, quoting the company number.

Source: The London Gazette and Companies House. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright. This page is provided by K2 Partners for information only and is not legal or financial advice.